Sponsor: Rubicon Genomics
Recording Date: 2/19/2014
Recording Time: 1 hour
This position entails bioinformatics analysis of cancer genome sequencing data from next generation sequencing technologies for assessing clinical outcomes. The applicant will be involved in NGS data analysis and interpretation, and clinical genomics knowledge mining and content derivation.
This is a position within TGen for a highly motivated scientist interested in designing, building, and managing a pipeline for Next Generation Sequencing (NGS) data and working collaboratively with interdisciplinary teams to develop technologies, tools, and bioinformatics solutions to support clinical translational research programs. The candidate will support analysis and interpretation of data derived from basic research and clinical studies. The candidate will work collaboratively with members of the Ivy Foundation’s Genomics Enabled Medicine for Glioblastoma team to analyze cancer and normal genomes to identify molecular signatures of therapeutic response and clinical outcome.
Candidate must have significant experience (demonstrated through peer reviewed publication) in the generation of Next Generation Sequencing (NGS) data from cancer specimens to identify somatic events. More emphasis is placed on experience in whole genome sequencing. This includes all of the following: 1) sample assessment and analyte extraction (DNA and RNA); 2) Next Generation Sequencing library preparation and quality control for multiple platforms; 3) Intimate knowledge of Next Generation Sequencing systems; 4) Knowledge of tools used for NGS data processing and analysis for the detection of single nucleotide variants, indels, copy number changes, and translocations. Development of databases for curating cancer genome alterations for data mining and querying.
The applicant must have lead authorship on published article(s) applying NGS to cancer genome profiling to understand clinical outcome of disease.
The applicant must have a deep understanding of cancer genomics and clinical research and a keen understanding of cancer pathways and targeted therapeutics as evidenced by publications in the field.
Education and Experience Requirements
Ph.D. in applicable field
If you are interested in seeing the most up to date job listings or to apply for a position,
please go to http://careers.tgen.org and submit your resume for this position. Please
take a moment to read about our employee benefits and learn more about TGen.
Please apply to all the jobs you are interested in. Only resumes submitted through the
TGen career website will be considered.
We value and support diversity in our workforce.
TGen’s mission is to contribute to and accelerate the research of complex diseases to not only add significantly to what is known about the genetics of each disease, but to also apply that knowledge immediately to help those patients sitting in front of us today and inform clinical decisions for the patients we see tomorrow. TGen tackles human disease utilizing all available technologies to more accurately diagnosis patients and identify the “Achilles’ heel” of each disease such that new, more efficacious and less costly treatments can be developed faster.
About the Ben & Catherine Ivy Foundation
The Ben & Catherine Ivy Foundation, based in Scottsdale, Arizona, was formed in 2005, when Ben Ivy lost his battle with glioblastoma multiforme (GBM). Since then, the Foundation has contributed more than $50 million to research in gliomas within the United States and Canada, with the goal of better diagnostics and treatments that offer long-term survival and a high quality of life for patients with brain tumors.
The Ivy Foundation sponsored GBM initiatives at TGen include research to understand why approximately two percent of GBM patients – the outliers – live far beyond the average survival time of 18 months. By precisely analyzing each patient’s genomic profile, TGen researchers hope to discover the genetic differences between those patients who survive only a few months and those who survive longer because their brain cancer develops more slowly. Using these genetic targets, TGen researchers hope to identify those patients most likely to benefit from the current standard of care and those who might best benefit from alternative or new experimental treatments. These novel treatments will be tested in first-in-patient clinical trial studies that will test promising new drugs that might extend the survival of GBM patients and expedite FDA approval and availability of new drugs that could benefit tens of thousands of brain cancer patients in the future.